Global African Horse Sickness Vaccines Market Size By Type (Live Vaccines, Killed Vaccines), By Application (Horses, Mules), By Region, And Segment Forecasts, 2023 to 2032

The Global African Horse Sickness (AHS) Vaccines Market was valued at USD 142 million in 2023 and is projected to reach USD 248 million by 2031, growing at a CAGR of 7.3% during the forecast period (2023–2031). The demand for AHS vaccines is rising due to increasing outbreaks of African horse sickness, particularly in endemic regions such as sub-Saharan Africa and parts of the Middle East. The growing awareness regarding equine health, the economic impact of equine diseases, and increasing investments in veterinary vaccine development are contributing to the market’s expansion.

AHS is a highly infectious and often fatal viral disease that affects horses, mules, and donkeys. With globalization, climate change, and the movement of equines across regions, the risk of AHS outbreaks has intensified, driving the need for effective vaccines.

Drivers:

1. Rising Incidence of AHS Outbreaks:

Outbreaks in endemic and at-risk regions are compelling governments and veterinary organizations to stockpile and distribute vaccines. Early detection and response efforts are supporting long-term vaccine adoption.

2. Growing Awareness of Equine Health Management:

Increased emphasis on preventive veterinary care, especially among commercial breeders, racing industries, and equine sport sectors, is supporting the uptake of AHS vaccines.

3. Government and NGO Veterinary Health Initiatives:

Collaborations between veterinary health bodies and regional governments to prevent transboundary animal diseases are driving mass immunization efforts, particularly in Africa and parts of Asia.

Restraints:

1. Cold Chain and Logistics Challenges in Remote Areas:

Maintaining vaccine potency requires strict cold chain management, which is often difficult in underdeveloped regions, limiting distribution and access.

2. Regulatory and Licensing Hurdles:

The AHS vaccine development and deployment are subject to stringent veterinary drug regulations, especially in non-endemic countries, which can delay approvals and market entry.

Opportunity:

1. Technological Advancements in Recombinant and Vector-based Vaccines:

Ongoing R&D is leading to the development of safer and more effective vaccines that could replace traditional live-attenuated formulations. This opens new market potential in countries previously hesitant to use live vaccines.

2. Expansion into Non-Endemic High-Risk Regions:

Due to global warming and international equine trade, regions like Europe and South Asia are witnessing increased surveillance, offering new market entry opportunities for AHS vaccines.

Market by System Type Insights:

Live Attenuated Vaccines held the largest share in 2023 owing to their historical effectiveness and widespread use in endemic regions. However, Recombinant Vaccines are projected to be the fastest-growing segment due to improved safety profiles and increased acceptance in non-endemic countries.

Market by End-Use Insights:

In terms of end-use, the Veterinary Hospitals & Clinics segment accounted for the largest market share in 2023. These institutions play a critical role in administering vaccines, especially during outbreaks. Meanwhile, the Research & Diagnostic Institutes segment is expected to register notable growth due to increased funding for vaccine development and disease surveillance.

Market by Regional Insights:

Africa dominated the market in 2023, with South Africa leading due to its status as an AHS-endemic zone and its developed veterinary infrastructure. Europe is emerging as a key market, particularly in Mediterranean countries at risk of disease incursion. The Asia-Pacific region is expected to exhibit the highest CAGR due to increasing awareness and equine population growth.

Competitive Scenario:

Prominent players in the Global African Horse Sickness Vaccines Market include Onderstepoort Biological Products, Zoetis Inc., Boehringer Ingelheim, MSD Animal Health, Ceva Santé Animale, and Indian Immunologicals Ltd. These companies are focusing on expanding distribution channels, investing in R&D for next-generation vaccines, and partnering with regional governments for disease control programs.

Key Market Developments:

2023: Onderstepoort Biological Products launched an improved AHS polyvalent live vaccine targeting multiple serotypes, increasing immunization efficacy.

2024: MSD Animal Health partnered with African veterinary authorities to supply emergency vaccine reserves for outbreak containment.

2025: Zoetis announced ongoing trials for a recombinant AHS vaccine designed to meet European biosafety standards.

Scope of Work – Global African Horse Sickness Vaccines Market

FAQs:

1) What is the current market size of the Global African Horse Sickness Vaccines Market?

The market was valued at USD 142 million in 2023.

2) What is the major growth driver of the Global African Horse Sickness Vaccines Market?

The primary growth driver is the rising incidence of African horse sickness outbreaks globally.

3) Which is the largest region during the forecast period in the Global African Horse Sickness Vaccines Market?

Africa is the largest regional market, driven by endemic disease prevalence and strong veterinary infrastructure.

4) Which segment accounted for the largest market share in the Global African Horse Sickness Vaccines Market?

The Live Attenuated Vaccines segment held the largest market share in 2023.

5) Who are the key market players in the Global African Horse Sickness Vaccines Market?

Key players include Onderstepoort Biological Products, Zoetis Inc., MSD Animal Health, Ceva Santé Animale, and Boehringer Ingelheim.